Jefferies raised the firm’s price target on Corvus Pharmaceuticals (CRVS) to $13 from $8 and keeps a Buy rating on the shares ahead of the report of Phase 1 interim data from soquelitinib in atopic dermatitis that is expected in December. The data from first two doses could provide the clinical proof of concept for the oral ITK inhibitor in broader I&I, or inflammation and immunology, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVS:
- Corvus Pharmaceuticals price target raised to $24 from $21 at Ladenburg
- Corvus Pharmaceuticals price target raised to $14 from $8 at Oppenheimer
- Corvus Pharmaceuticals Reports Q3 2024 Financial Results
- Corvus Pharmaceuticals reports Q3 EPS (60c), consensus (11c)
- Corvus Pharmaceuticals options imply 17.7% move in share price post-earnings